Welcome to our dedicated page for AVITA Medical SEC filings (Ticker: AVHHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVITA Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVITA Medical's regulatory disclosures and financial reporting.
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. director Woody Joseph Fralin bought a total of 20,000 shares of Common Stock in open-market transactions. The purchases occurred on June 1 and 2 at prices between $4.18 and $4.34 per share, bringing his direct holdings to 20,000 shares.
AVITA Medical, Inc. CFO David D. O'Toole acquired 5,000 shares of common stock in a Form 4 transaction. The shares were obtained through the company’s Employee Share Purchase Plan at $3.0515 per share, based on an 85% discount to the December 1, 2025 closing price. Following this acquisition, he directly holds 150,927 shares, including unvested RSUs.
AVITA Medical, Inc. President and CEO Vance Cary Guy acquired 5,000 shares of common stock through the company’s Employee Share Purchase Plan. The shares were purchased at $3.0515 per share, equal to 85% of the closing price on December 1, 2025, for the ESPP period that ran through May 31, 2026.
After this transaction, he holds 40,771 shares directly, a figure that includes unvested restricted stock units. The acquisition is classified as a grant or award and was exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related, routine purchase rather than an open-market trade.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of 2,000 shares of common stock at a price of $4.26 per share. Following this transaction, he directly holds 145,927 shares, which the disclosure states include unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported an open-market purchase of common stock. He bought 2,000 shares at $4.24 per share, increasing his direct holdings to 143,927 shares. The reported total includes unvested restricted stock units, indicating both vested and unvested equity exposure.